Safety and tolerability of antiretroviral therapy among HIV-Infected children and adolescents in UGANDA

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 274-280

  Tukei, Vincent J ^a   Asiimwe, Alice ^a   Maganda, Albert ^a   Atugonza, Rita ^a   Sebuliba, Isaac ^a   Bakeera Kitaka, Sabrina ^b   Musoke, Phillipa ^b,c   Kalyesubula, Israel ^a   Kekitiinwa, Adeodata ^a  

^a MULAGO HOSPITAL   (Uganda)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c MAKERERE UNIVERSITY   (Uganda)

Author keywords

Antiretroviral therapy; Child; Drug toxicity; HIV

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AMNESIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; CARDIOMYOPATHY; CHILD; CHILDHOOD DISEASE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GYNECOMASTIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NAUSEA AND VOMITING; NEURITIS; NIGHTMARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UGANDA;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HIV; HIV INFECTIONS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; QUESTIONNAIRES; UGANDA;

EID: 84859739655     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182423668     Document Type: Article

References (36)

1. Banerjee T, Pensi T, Banerjee D, et al. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. Ann Trop Paediatr. 2010;30: 27-37.
2. Komatsu R, Korenromp EL, Low-Beer D, et al. Lives saved by global fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis. 2010;10: 109.
3. Ndirangu J, Newell ML, Tanser F, et al. Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? AIDS. 2010;24: 593-602.
4. Palladino C, Bellon JM, Jarrin I, et al. Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006. AIDS Res Hum Retroviruses. 2009; 25: 1091-1097.
5. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44: 456-462. (Pubitemid 46555382)
6. Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8: 318-322.
7. Laurent C, Bourgeois A, Mpoudi-Ngole E, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses. 2008;24: 393-399. (Pubitemid 351457754)
8. Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170: 229-238. (Pubitemid 38134804)
9. Padua CA, Cesar CC, Bonolo PF, et al. High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res. 2006;39: 495-505.
10. Van Griensven J, Zachariah R, Rasschaert F, et al. Stavudine- and nevirapine- related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010;104: 148-153.
11. Rhoads MP, Lanigan J, Smith CJ, et al. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011;57: 404-412.
12. Jacobson DL, Williams P, Tassiopoulos K, et al. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr. 2011;57: 413-420.
13. Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11: 104-113.
14. Waters L, Nelson M. Why do patients fail HIV therapy? Int J Clin Pract. 2007;61: 983-990. (Pubitemid 46744073)
15. Cardoso SW, Grinsztejn B, Velasque L, et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses. 2010;26: 865-874.
16. Minzi OM, Irunde H, Moshiro C. HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania. Tanzan J Health Res. 2009;11: 5-10.
17. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16: 1363-1370. (Pubitemid 34722068)
18. Sauvageot D, Schaefer M, Olson D, et al. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children ,5 years of age. Pediatrics. 2010;125: E1039-E1047.
19. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Available at: http: //www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed October 11, 2010.
20. World Health Organization. Scaling up antiretroviral therapy in resourcelimited settings: treatment guidelines for a public health approach. 2003 revision. Available at: http: //www.who.int/3by5/publications/documents/ arv-guidelines/en/index.html. Accessed October 11, 2010.
21. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: recommendations for a public health approach(2006 revision). Available at: http: //www.who.int/hiv/pub/paediatric/infants/en/ index.html. Accessed October 11, 2010.
22. National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events: December 2004. Available at: http: //www.niaid.nih.gov/LabsAndResources/resources/ DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. Accessed October 11, 2010.
23. Kumarasamy N, Venkatesh KK, Devaleenol B, et al. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr. 2009;55: 155-159.
24. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170: 57-65.
25. Bristol-Myers Squibb Canada. Sustiva (Efavirenz) Product Monograph. Montreal, Canada: Bristol Myers Squibb Canada; 1999. Available at: http: //www.bmscanada.ca/static/products/en/pm-pdf/Sustiva-E-26%20Nov%202010-PM-DIST- CLN.pdf. Accessed April 20, 2011.
26. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6: 187-196. (Pubitemid 41601130)
27. Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res. 2010;85: 201-209.
28. Masaisa F, Gahutu JB, Mukiibi J, et al. Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. Am J Trop Med Hyg. 2011;84: 456-460.
29. Hepburn MJ, Dyal K, Runser LA, et al. Low serum vitamin B12 levels in an outpatient HIV-infected population. Int J STD AIDS. 2004;15: 127-133. (Pubitemid 38221762)
30. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91: 301-308. (Pubitemid 28018758)
31. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIVinfected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26: 315-319. (Pubitemid 32451757)
32. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29: 54-57. (Pubitemid 34094307)
33. Owiredu WK, Quaye L, Amidu N, et al. Prevalence of anaemia and immunological markers among ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci. 2011;11: 2-15.
34. World Health Organization. New progress and guidance on HIV treatment.Available at: http: //www.who.int/hiv/pub/arv/ARTfactsheet/en/index. html. Accessed November 01, 2011.
35. Ross AC, McComsey GA. Cardiovascular disease risk in pediatric HIV: the need for population-specific guidelines. J Acquir Immune Defic Syndr. 2011;57: 351-354.
36. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375: 123-131.